Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
EBV EARLY ANTIGEN IGG ANTIBODY |
|||||||||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2229 Geisinger Epic ID: 32952 | ||||||||
SPECIMEN COLLECTION |
|||||||||
Specimen type: |
Serum | ||||||||
Preferred collection container: |
|||||||||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
|
||||||||
Specimen required: |
0.5 mL serum. Minimum 0.2 mL. | ||||||||
SPECIMEN PROCESSING |
|||||||||
Specimen processing instructions: |
Allow to clot. Centrifuge and submit 0.5 mL serum. | ||||||||
Transport temperature: |
Refrigerated (preferred). Room temperature (stable 8 hours) and frozen specimens also acceptable. | ||||||||
Specimen stability: |
Room temperature: 8 hours; 2-8ÂșC: 96 hours. Frozen: 6 months. | ||||||||
Rejection criteria: |
Specimen stability exceeded; specimen grossly hemolyzed. | ||||||||
TEST DETAILS |
|||||||||
Interpretation guide: |
This test is for the qualitative determination of IgG antibodies to EBV early antigen. |
||||||||
CPT code(s): |
86663 | ||||||||
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | |||||||||
Test includes: |
Antibody detection to EBV Early Antigen IgG. | ||||||||
Methodology: |
Chemiluminescence |
||||||||
Synonyms: |
EBV Early Antigen-Diffuse EBV EA-D EBVEAR
|
||||||||
Clinical significance: |
Epstein-Barr virus (EBV) is responsible for infectious mononucleosis (IM) and has also been implicated in Burkitt's lymphoma and nasopharyngeal carcinoma. EBV-EA (Epstein-Barr virus early antigen) IgG antibodies are associated with primary (acute) stage of EBV infection and are generally undetectable six months after clinical onset of the disease. A negative result does not rule out current EBV infection, and a positive result should be substantiated with an EBV-IgM test. | ||||||||
Doctoral Director(s:) |
Hoi-Ying Elsie Yu PhD, DABCC | ||||||||
Review Date: | 12/13/2022 |